Gemini Therapeutics Inc (NASDAQ: GMTX) announced early data from its Stage 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) subordinate to dry AMD.  It is a dose-escalation trial of GEM103 The reGAtta is a dosage appreciation pilot of GEM103, intravitreally managed recombinant human […]